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Human immunodeficienty virus (HIV) infection is suppressed but not eliminated by antiretroviral
drugs. Viral persistence in the face of therapy has been explained by viral latency, lowered effectiveness
of drugs in some anatomical sites and cell types, and cell-to-cell spread. These mechanisms allow for
drug-sensitive virus to persist despite treatment. Understanding the persistence mechanism at work
at different times after infection, including the time of initial infection immediately following transmis-
sion when reservoirs are first formed, will reveal if we are at the limit of what can be achieved with
the current therapy paradigm of suppressing ongoing virus replication with drugs. We discuss some
of the possible reasons why HIV persists at different points on the infection timeline, focusing on
the role ongoing replication may have in maintaining the infection despite drugs at early times postexpo-
sure.Introduction
Antiretroviral therapy (ART), which targets ongoing human
immunodeficienty virus (HIV) replication, has been extremely
successful at containing HIV infection. However, there is no
possibility of curing an established HIV infection with ART,
and the reasons for this are the cause of some debate. Have
we reached the limit of what can be achieved by suppressing
ongoing replication? There is growing interest in this ques-
tion in the context of early infection, since it may be pos-
sible to suppress infection before the long-term reservoirs of
virus, which are refractory to ART, are established. This is
precisely the logic behind prophylactic administration of drugs
before or immediately after virus exposure (Cardo et al., 1997;
Grant et al., 2010). Even if the prophylactic window is missed,
there is emerging evidence that administration of drugs very
early following infection reduces the viral loads achieved
subsequently (Ananworanich et al., 2012; Strain et al., 2005).
Both prophylaxis and early treatment increase the relevance
of understanding how HIV infection becomes established
early on the infection timeline (Figure 1), which may differ
from the principles underlying persistence once the infection
is fully established. Understanding early infection may present
opportunities for intervention aimed at either increasing the
effectiveness of prophylaxis or ameliorating the course of
infection.
In this Perspective, we first consider the mechanisms of HIV
drug insensitivity as currently understood. These break down
into mechanisms that require new cycles of viral replication
and those that do not, and depend on anatomical sites and
cell types with lowered drug penetration, cell-to-cell HIV
spread, and viral latency. We then discuss how each of these
mechanisms may play a role at different points on the HIV
infection timeline as outlined in Figure 1, with particular focus
on the time points before and soon after exposure.132 Cell Host & Microbe 12, August 16, 2012 ª2012 Elsevier Inc.Latent Infection and Other Types of Nonreplicating
Reservoirs
Current ART is very effective and may even shut down virus
replication completely (Shen et al., 2008). However, HIV has
a non-replication-based mechanism for insensitivity to drugs,
which consists of latently integrated provirus in long-lived cells.
In this state, the integrated provirus can remain quiescent and
persist for the life of the cell, many years in some cell types.
The provirus will be duplicated along with the cellular DNAwhen-
ever the cell divides. The most common view is that the quies-
cent provirus is harbored by a population of latently infected
CD4+ memory T cells (Trono et al., 2010). This population may
expand by homeostatic proliferation, and hence the reservoir
need not decay with time (Chomont et al., 2009). Occasionally,
a memory T cell containing the quiescent provirus will be acti-
vated. This will lead to transcription factors NFAT and NF-kB
binding to their target sites on the viral long terminal repeat
(LTR) and initiating transcription of the viral genome. Once tran-
scription is initiated, it will be amplified by a positive feedback
loop mediated by the HIV protein Tat (Trono et al., 2010), giving
rise to actively infected T cells capable of reinitiating ongoing
infection if drugs are discontinued.
A variation on this scenario is that infection is not truly latent or
in memory T cells. Instead, long-lived cells such as hematopoi-
etic stem cells or neurons are infected. These cells are not killed
by the virus. Therefore, they may either produce a constant
stream of virions from the integrated provirus or, in the case of
hematopoetic cells, differentiate into actively infected cells
(Trono et al., 2010). This virus population would be distinct
from the virus present in the latently infected T cell pool, and
such a population has been identified in some individuals on
ART (Bailey et al., 2006). Like latency, no new infections occur
in the presence of drugs but ongoing infection can be rekindled
upon therapy interruption. Since replication is expected to
Pre-exposure 
prophylaxis
Post-exposure
prophylaxis
Early therapy
reduces set point
ART+ purging of 
latent reservoir
Exposure
Early 
reservoirs
Mature 
reservoirs
Acute systemic infection Stable viremiaLocal infection close to entry site 
DCs infected
T cells infected
Lymph node seedingViral
events
Eclipse phase Early detectable 
infection
Viral RNA (PCR) p31+ (ELISA)
Steady state 
infection
Limit of detection
Therapies
tested
10 0011
Time (days, log scale)
1000
Pl
as
m
a 
vi
ra
l R
N
A
 (c
op
ie
s 
pe
r m
l)
102
104
106
Figure 1. Timeline of HIV Infection and Treatment
After exposure, infection can be roughly staged into the eclipse phase, early detectable infection, and steady-state infection. No virus can be detected in the
eclipse phase, but reservoir formation has already begun since the infection is incurable 2–3 days postexposure. After approximately 10 days, infection starts to
seed the draining lymph nodes and becomes detectable by PCR for viral RNA. This period is known by Fiebig stages I–V (Fiebig et al., 2003), with each stage
adding a detection modality. Early therapy that does not consist of prophylaxis is given during this time window. Infection becomes acute and peaks after about
day 20, and it is at this time that the latent reservoir is thought to be seeded. After about 100 days, the infection settles into a steady state, where it is controlled by
ART in most individuals, but re-emerges quickly upon therapy interruption. Purging of the latent reservoir is usually considered at this point on the infection
timeline. The therapeutic modalities currently investigated for each stage of infection are shown in the gray box below the graph, with the box and graph sharing
the same timeline. Viral events are in the blue box, which is also on the timeline. X axis is in time days, y axis is plasma viral RNA. Both are on a log scale. Elements
in the figure are modified with permission from Keele et al. (2008a), Copyright (2008) National Academy of Sciences, USA.
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tected sequence evolution during ART in virions circulating in
the plasma supports the presence of a nonreplicating reservoir.
The currently proposed approach to eliminate the latent
reservoir is to purge the latently infected cells by activating HIV
production in these cells using inhibitors to histone deacety-
lases, which prevent transcription from the viral LTR promoter
(Archin et al., 2012a; Lehrman et al., 2005; Sagot-Lerolle et al.,
2008; Siliciano et al., 2007). The cells actively producing virus
are expected to be eliminated either because the virus is cyto-
toxic or because cytotoxic lymphocytes will recognize and kill
actively infected cells (Shan et al., 2012). Drugs are administered
at the same time to prevent the actively infected cells from
infecting new cells.
Reservoir Mechanisms that Require Virus Replication
I) Decreased Drug Levels
While HIV can be described as transmitting relatively poorly, it is
the great persister. Despite the detection of potent anti-HIV
antibodies in some patients (Li et al., 2007), a cellular immune
response that is thought to at least be able to contain infection(Walker et al., 1986), or effective ART, no sterilizing clearance
of established infection is known to occur. The immune response
is a natural pressure the virus needs to deal with. Some of
the strategies that HIV uses to replicate despite the immune
responsemay also enable it to replicate in the presence of drugs.
One mechanism of persistence based on ongoing replication
is infection in anatomical sites where drugs are to some degree
excluded, such as the brain (Trono et al., 2010), genital tract (Cu-
Uvin et al., 2010; Deleage et al., 2011), and dramatically in the gut
(Stevenson et al., 2012). Suboptimal intracellular drug levels
can also ensue: cells can actively pump drugs out using the
P-glycoprotein transporter (Schuetz et al., 1999). For the nucle-
oside/nucleotide analog class of drugs included in almost all
regimens, cellular phosphorylation to the triphosphate form is
necessary for these inhibitors to compete with the native nucle-
otide pool for incorporation into the HIV cDNA and lead its
premature termination. Since the kinases involved tend to be
active during cell proliferation, at least some of these com-
pounds are poorly phosphorylated in quiescent cells (Davis
et al., 2001), where the initial local infection is reported to take
place (Zhang et al., 1999). Both the P-glycoprotein-based effluxCell Host & Microbe 12, August 16, 2012 ª2012 Elsevier Inc. 133
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in macrophages (Jorajuria et al., 2004; Richman et al., 1987).
II) Cell-to-Cell Spread
A second mechanism for drug insensitivity during ongoing repli-
cation is infection by cell-to-cell spread (Sigal et al., 2011). This is
a mode of directed HIV transmission that aims the infected cell’s
virus load at a few nearby cells at very close range through the
formation of direct interactions between the infected and unin-
fected cells (Dimitrov et al., 1993; Hu¨bner et al., 2009; Jolly
et al., 2011; Rudnicka et al., 2009; Sattentau, 2008; Sowinski
et al., 2008). Cell-to-cell transmission takes advantage of nor-
mally occurring interactions between immune cells that form
physical contacts along which the virus is delivered to the unin-
fected target cell. It is a receptor-mediated process and not
dependent on cell fusion (Sattentau, 2008). During cell-to-cell
transmission, many virus particles are transmitted to a single
uninfected target cell, and this makes it more probable that at
least one virus particle stochastically escapes HIV inhibitors
such as drugs or antibodies and proceeds to infect the cell (Sigal
et al., 2011).
Cell-to-cell spread of HIV is usually investigated between
T cells but also works when the donor cell is an infected macro-
phage (Carr et al., 1999). Moreover, donor cells do not need to
become actively infected themselves. Dendritic cells (DCs) can
bind virus on their surface by interaction with DC-SIGN and
transmit HIV in trans to T cells when the latter form immunolog-
ical synapses with DCs as part of the process of antigen
presentation (Geijtenbeek et al., 2000). Virus particles are not
only concentrated by DCs for transmission to T cells, but also
transported by DCs to lymph nodes, where the numbers of
susceptible T cells is high (Embretson et al., 1993; Pantaleo
et al., 1993). HIV-infected T cells are also verymotile and perform
a similar function for the virus (Murooka et al., 2012). At the lymph
nodes, HIV opsonized by antibodies can be captured by follicular
dendritic cells and remain infectious for months (Heath et al.,
1995; Keele et al., 2008b). Closer to the site of exposure, the
virus can be captured and presented to CD4+ T cells by genital
epithelial cells (Dezzutti et al., 2001; Maher et al., 2005; Wu
et al., 2003). This is also true of mammary epithelial cells
(Dorosko and Connor, 2010). Lastly, virus capture need not
only occur by a cell: amyloid fibers in the semen can bind and
efficiently transmit HIV to any susceptible cells they come in
contact with (Mu¨nch et al., 2007). All these mechanisms allow
for directed virus spread and reduce drug sensitivity due to the
sheer number of virus particles infecting a single target cell.
Because of the fast mutation rate of HIV, replication in the
context of either an anatomical reservoir or cell-to-cell spread
should lead to some accumulation of neutral mutations unless
replication is not continuous (Sigal et al., 2011). However, there
are several reasons why mutations in the viral sequence may
not necessarily lead to drug resistance and the associated failure
of the ART regimen (virologic failure). One reason may be that
drug-resistance mutants may arise but the fitness cost of muta-
tions to combination therapy (Bangsberg et al., 2006) may make
them unable to spread. A second reason may be that a small
population size of infected cells introduces high levels of drift,
which counters the selection of more fit mutants—the variant
that survives is determined more by chance than fitness (Brown
and Richman, 1997). Hence, it is possible for reservoirs based on134 Cell Host & Microbe 12, August 16, 2012 ª2012 Elsevier Inc.ongoing replication to be a cause of persistence of low-level
infection, and yet not lead to virologic failure and infection
breakout to high viral titers.
It is also likely that anatomical reservoir mechanisms coop-
erate with cell-to-cell spread to further increase insensitivity
to drugs: shear flow, which inhibits cell-to-cell spread (Souris-
seau et al., 2007), is usually absent from areas proposed to be
anatomical reservoirs. Niches where cells can be in close
contact for extended periods should also be readily available
at these anatomical sites.
Drug Insensitivity in the Prophylaxis Treatment Window
In the first hours to days after HIV exposure, infection is thought
to be local, close to the site of virus entry. The first cells reported
to be infected are DCs or Langerhans cells (Hu et al., 2000),
followed by resting CD4+ T cells (Zhang et al., 1999). After infec-
tion establishes at the site of entry, it seeds the surrounding
lymph nodes. This leads to the transition to a systemic infection
that proceeds to become acute, with high levels of virus in the
plasma (for Review, see Haase, 2010). The infection now initiates
a strong immune response and subsides into an apparently
asymptomatic phase with a stable level of viremia that generally
lasts years.
Very early infection may be cleared by pre- and post-exposure
prophylaxis (Figure 1), which attempts to clear the infection
before it forms drug insensitive reservoirs. Several clinical trials
have investigated the effectiveness of pre-exposure prophylaxis
(PrEP). The results are encouraging but highly variable. Two
studies (CAPRISA 004 and VOICE) tested a gel containing the
antiretroviral tenofovir that is applied by women before and after
intercourse. Five studies (VOICE, Partners PrEP, iPrEX, TDF2,
and FEM-PrEP) tested a regimen of one or two antiretroviral
drugs taken orally on a constant basis. The CAPRISA 004 trial
found the gel to be protective (Abdool Karim et al., 2010), while
the VOICE trial did not (MTN Statement on Decision to Dis-
continue Use of Tenofovir, http://www.mtnstopshiv.org/node/
3909). The Partners PrEP (Baeten et al., 2012), iPrEX (Grant
et al., 2010), and TDF2 (Thigpen et al., 2012) trials found the
oral PrEP regimen effective, while FEM-PrEP (Van Damme
et al., 2012) and VOICE (IH modifies ‘VOICE’ HIV prevention
study in women: oral tenofovir discontinued in clinical trial;
http://www.nih.gov/news/health/sep2011/niaid-28.htm) were
stopped due to futility. In the trials where protection was
observed, the reduction in the number of infections was itself
variable: 44% (iPrEX), 54% (CAPRISA 004, highest adherers),
63% (TDF2), and 73% (PrEP). Except for CAPRISA 004, all
percentages are for the coformulated oral tenofovir and emtrici-
tibine regimen. Differences may reflect the different populations
that were enrolled in the studies. Partners PrEP, which showed
the best protection, enrolled established discordant couples.
The choice of study population may affect multiple parameters.
A very important parameter is adherence, which may determine
if the drugs are present at all during exposure. However, it is
likely not the only parameter, and others, such as how the trans-
mission takes place, may also play an important role (Cohen and
Baden, 2012).
Can drug insensitivity mechanisms play a role in HIV break-
through despite PrEP and account for some of the variability
observed in these studies? There are several ways drug
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viral concentrations at the site of exposure. This may be espe-
cially relevant to future prophylactic modalities such as gene
therapy-based antibody expression (Balazs et al., 2012). Here,
the challenge would be to accumulate sufficiently high-antibody
titers in vaginal or rectal mucosa, the sites of initial infection. A
second way for drug insensitivity to occur is if incoming cell-
free virus is captured and efficiently transmitted to T cells or
macrophages by resident DCs at the exposure site. A third,
and extensively debated, possibility is that initial infection is
mediated not only by cell-free virus, but also by cell-associated
virus (for Review, see Anderson et al., 2010). This may lead to
cell-to-cell spread, which would reduce sensitivity to drugs. In
addition, it would confer the benefit—to the virus—of potentially
transporting it to productive sites of infection.
Evidence that cell-to-cell transmission may occur during the
initial exposure to the virus includes the following: (1) unpro-
tected sex leads to immune cells from the infected partner
making contact with T cells from the uninfected partner (Kingsley
et al., 2009; Peters et al., 2004); (2) HIV can be readily transmitted
in this type of mixed lymphocyte reaction (Sigal et al., 2011);
(3) cell-associated infection was demonstrated in SIV vaginal
challenge of macaques (Salle´ et al., 2010; Weiler et al., 2008);
(4) the concentration of infected cells required for transmission
in the macaque model was within the physiological range,
while infection with cell-free viruses by vaginal SIV challenge
required superphysiological doses; and (5) for mother-to-child
transmissions, the number of infected cells in breast milk
and vagina has been demonstrated to correlate with the prob-
ability of infection (John et al., 2001; Rousseau et al., 2004;
Tuomala et al., 2003).
If drug insensitivity through cell-to-cell spread is involved in the
initial avoidance of drug-mediated suppression and underlies
the variable efficacy of PrEP therapies, the effect need not be
large since PrEP does not decrease successful transmission
by orders of magnitude in studies to date. Therefore, a 2-fold
decrease in sensitivity may result in a similar increase in the
number of infected individuals. In this case, microbicidal and
other PrEP therapies may need to include or be combined with
ways to inhibit cell-to-cell HIV spread. Screening for host and
chemical factors that interfere with the interaction between the
incoming infected donor cells and the resident uninfected target
cells could help arrive at the necessary therapeutic combination.
Drug-Insensitive Infection after Prophylaxis No Longer
Works
Postexposure, the time window during which infection can be
cured by drugs ranges from 24 hours (intravenous injection
[Tsai et al., 1998]) to 48 hours (vaginal challenge [Otten et al.,
2000]), with the limitation that the data is by necessity from
a simian infection model and the number of animals used in the
studies is small. Bearing in mind this limitation, it seems that after
the first few days have elapsed, the curative window closes and
the first HIV drug-insensitive reservoirs are formed. What is the
nature of these reservoirs?
Since resting T cells are infected within a 2–3 day window after
vaginal challenge, it is possible that a latent reservoir is estab-
lished and can become self-sustaining by homeostatic expan-
sion. However, it is more likely that the latent reservoir needsthe acute phase of infection to seed sufficient cells (Chun
et al., 1998) and the reservoir may continue to fill thereafter.
Therefore, even if the latent reservoir is present in the first
2–3 days after infection, it is likely to be not fully formed. In
support of this, early treatment initiated within approximately
the first month postexposure reduced HIV set-point levels during
mature infection (Ananworanich et al., 2012; Strain et al., 2005).
It is important to understand whether the early reservoirs that
exist at this point in the presence of ART involve drug-
insensitive ongoing cycles of replication. Early reservoirs may
fill other, possibly more stable reservoirs, such as the latent
reservoir. Can we determine if ongoing replication takes place
during this early phase of infection despite the presence of
antiretroviral drugs? If all replication were shut down with ART,
the rate of decay in the number of infected cells after therapy
has been started would not affect the number of latent cells
later, since no new cells would be infected in this phase. At least
one study shows that this is not the case: the number of
infected CD4+ resting cells a year postinfection does correlate
with the area under the viral load curve after ART has been
initiated (Archin et al., 2012b). Such transient reservoirs, possibly
based on ongoing replication, await further confirmation. If
they exist, they may mediate the transition between a curable
infection and an infection that had rooted itself by drug insen-
sitive reservoirs.
Mature Infection
There is widespread agreement that latently infected cells are
present during the long phase of stable viremia in HIV infection.
There is some debate whether latency is the only reservoir mech-
anism at this stage. Intensification of therapy with more drugs
does not lead to further declines in plasma virus levels (Trono
et al., 2010), consistent with the idea that drugs at current levels
shut down all replication. However, infected cells at this point on
the infection timeline do contain detectable unintegrated DNA
(Chomont et al., 2009), which is labile and not expected to persist
over long periods without new infection. The unintegrated HIV
DNA is similar in sequence to rebounding virus after therapy
interruption, indicating that it is the source of the rebounding
virus (Sharkey et al., 2011). Further, intensification of ART by
addition of the integrase inhibitor raltegravir gives rise to an
increase in unintegrated DNA, consistent with new infections
occurring (Buzo´n et al., 2010).
One way to explain these divergent results is that replication
does not occur in the plasma but happens in other anatomical
compartments. In simian models, the virus during ART is mostly
concentrated in the lymphoid tissues and the GI tract (North
et al., 2010). If ongoing replication occurs in the GI tract and
not in the plasma, it implies that the GI tract would not recover
CD4+ cell numbers with ART to the same degree as the plasma.
This seems to be the case: human-gut-associated lymphoid
tissue does not recover its CD4+ cells despite prolonged sup-
pression by ART (Chun et al., 2008). In some individuals on
ART with clinically undetectable plasma viral loads, virus levels
remain detectable in the cervix (Cu-Uvin et al., 2010) and semen
(Politch et al., 2012). Infected macrophages have been detected
during ART in the semen (Deleage et al., 2011), which is only
possible with new cycles of infection since macrophages are
too short lived to form a stable latent reservoir. Evidence forCell Host & Microbe 12, August 16, 2012 ª2012 Elsevier Inc. 135
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sequence divergence and the frequency of resistance mutations
is elevated relative to peripheral blood in individuals on ART
(Wagner et al., 2009).
If some ongoing replication does take place in the face of ART
during mature infection, its causes—low-drug penetration, cell-
to-cell spread, or other mechanisms—should be tackled before
the approach to purge the latent reservoir is expected to bear
fruit. Otherwise, new infections during the purging process will
be created, which may replenish the reservoir and thwart the
purging efforts.Conclusion
Barring a stem-cell transplant from a donor who lacks the CCR5
HIV coreceptor, antiretroviral drugs that inhibit virus replication
have been the only effective treatment so far to control HIV infec-
tion. But though they suppress the infection, they do not cure it
unless used very near the time of exposure, and even in this
case they often fail. Have we reached the limit of what can be
achieved with treatments that suppress viral replication because
the limiting factors now are nonreplicating reservoirs such as the
latent reservoir and adherence to therapies on the part of the
patients? Or, is there still work to be done by therapies that
prevent viral replication (Cohen, 2011)? Results from studies
that use histone deacetylase inhibitors to purge the latent reser-
voir by activating the virus (Archin et al., 2012a; Lehrman et al.,
2005; Sagot-Lerolle et al., 2008; Siliciano et al., 2007) did not,
as of yet, convincingly show that they can reduce this reservoir.
If they succeed in doing so, then the true importance of the latent
reservoir can be finally evaluated. Conversely, if anatomical
reservoirs and cell-to-cell spread are also involved in viral persis-
tence in the face of ART, treatments that prevent ongoing re-
plication in these reservoirs will be effective in further reducing
or eliminating infection. But, the treatments may need to be
substantially different from what is currently used, since simply
treating with more drugs does not seem to increase efficacy.
Early treatment is one place where drugs may have additional
therapeutic value, and looking at how HIV infection establishes
itself at those points on the infection timeline may reveal the
nature of the mechanisms that this virus uses to persist.ACKNOWLEDGEMENTS
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